AstraZeneca to present overall survival data from four pivotal Phase III trials in Presidential Symposia at ESMO 2026 featuring Sone-Ve, IMFINZI® (durvalumab), TAGRISSO® (osimertinib) and savolitinib
Key takeaways
- AstraZeneca is poised to deliver breakthrough survival data across four key oncology trials at ESMO, potentially redefining treatment standards and boosting its pipeline profile.
- 60% of patients have CLDN18.2 expression ≥25% in advanced gastric/GEJ cancers
- 100 abstracts presented at ESMO
- 5 pivotal Phase III trials
What happened
AstraZeneca will present overall survival data from four Phase III trials at the European Society for Medical Oncology Congress, Oct. 23‑27, 2026. The trials cover a new antibody‑drug conjugate for gastric cancer (Sone‑Ve), a combination of TAGRISSO® with savolitinib for MET‑driven lung cancer, a first‑line maintenance combo of IMFINZI® with tarlatamab for small‑cell lung cancer, and a perioperative IMFINZI® plus enfortumab vedotin regimen for bladder cancer. The company highlights that the…
Why it matters
These presentations showcase AstraZeneca’s strategy of combining targeted therapies and immuno‑oncology agents across multiple tumor types, potentially setting new treatment standards. The data could influence future regulatory approvals, reimbursement decisions, and the company’s pipeline positioning. Positive…
Short-term and longer-term
Short-term. Over the next few days, traders should watch for the release of the overall survival data and any accompanying commentary from AstraZeneca’s leadership.
Longer-term. In the coming months, investors will assess how these data fit into AstraZeneca’s broader oncology strategy and long‑term growth prospects.